PubRank

Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.

PubWeight™: 3.43‹?› | Rank: Top 1%

🔗 View Article (PMID 26361971)

Published in Lancet Oncol on September 08, 2015

Authors

Susanna Hegewisch-Becker1, Ullrich Graeven2, Christian A Lerchenmüller3, Birgitta Killing4, Reinhard Depenbusch5, Claus-Christoph Steffens6, Salah-Eddin Al-Batran7, Thoralf Lange8, Georg Dietrich9, Jan Stoehlmacher10, Andrea Tannapfel11, Anke Reinacher-Schick12, Julia Quidde13, Tanja Trarbach14, Axel Hinke15, Hans-Joachim Schmoll16, Dirk Arnold17

Author Affiliations

1: HOPE-Practice for Oncology, Hamburg, Germany. Electronic address: hegewisch@t-online.de.
2: Kliniken Maria Hilf GmbH, Department of Hematology, Oncology and Gastroenterology, Mönchengladbach, Germany.
3: Practice for Oncology, Münster, Germany.
4: Lahn-Dill-Kliniken, Department of Hematology/Oncology, Wetzlar, Germany.
5: Practice for Oncology, Gütersloh, Germany.
6: MVZ Hematology/Oncology, Stade, Germany.
7: KrankenhausNordwest, UCT University Cancer Center, Frankfurt, Germany.
8: AsklepiosKlinikum, Department for Hematology/Oncology, Weißenfels, Germany.
9: KlinikumBietigheim, Department of Gastroenterology/Hematology/Oncology, Bietigheim-Bissingen, Germany.
10: Institut für Tumorgenetik, Bonn, Germany.
11: Institute for Pathology, Ruhr-University, Bochum, Germany.
12: St Joseph Hospital, Ruhr University, Bochum, Germany.
13: University Medical Center Hamburg-Eppendorf, Department of Oncology, Haematology, Bone Marrow Transplantation with Section Pneumology; Hubertus Wald Tumorzentrum, University Hospital Eppendorf, Hamburg, Germany.
14: iOMEDICO AG, Freiburg, Germany.
15: WiSP Wissenschaftlicher Service Pharma GmbH, Langenfeld, Germany.
16: Department of Hematology/Oncology, University Hospital, Halle (Saale), Germany.
17: Klinik für Tumorbiologie, Freiburg, Germany.

Associated clinical trials:

Optimal Maintenance Therapy With Bevacizumab After Induction in Metastatic Colorectal Cancer (CRC) | NCT00973609

A Single Arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Maintenance Treatment With Capecitabine Plus Cetuximab in Metastatic Colorectal Cancer | NCT02717923

Articles citing this ↘

Maintenance treatment in metastatic colorectal cancer. Lancet Oncol (2015) 1.00

Maintenance treatment in metastatic colorectal cancer. Lancet Oncol (2015) 0.95

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. Ann Oncol (2016) 0.82

Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism. Nat Commun (2016) 0.78

From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat Rev Clin Oncol (2016) 0.78

Prediction of the efficacy of immunotherapy by measuring the integrity of cell-free DNA in plasma in colorectal cancer. Cancer Sci (2016) 0.76

Feasibility of alternating induction and maintenance chemotherapy in pancreatic cancer. Sci Rep (2017) 0.75

Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives. Gastrointest Cancer (2016) 0.75

Maintenance therapy for metastatic colorectal cancer. Lancet Oncol (2015) 0.75

Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies. Ther Adv Med Oncol (2016) 0.75

Meta-analysis comparing maintenance strategies with continuous therapy and complete chemotherapy-free interval strategies in the treatment of metastatic colorectal cancer. Oncotarget (2016) 0.75

Maintenance treatment in metastatic colorectal cancer - Authors' reply. Lancet Oncol (2015) 0.75

Yttrium-90 Radioembolization for Metastatic Colorectal Cancer: Outcomes by Number of Lines of Therapy. Semin Intervent Radiol (2017) 0.75

Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis. Oncotarget (2017) 0.75

Present and future of metastatic colorectal cancer treatment: A review of new candidate targets. World J Gastroenterol (2017) 0.75

Articles by these authors ⇆

Maintenance treatment in metastatic colorectal cancer - Authors' reply. Lancet Oncol (2015) 0.75

Immunohistochemical and molecular characterizations in urothelial carcinoma of bladder in patients less than 45 years. J Cancer (2017) 0.75

Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer - Results from a prospective cohort study. Clin Epidemiol (2015) 0.75